IIT-M incubated Cygni Energy opens 4.8 GWh BESS Gigafactory near Hyderabad
Hyderabad-headquartered Cygni Energy opened a 4.8 GWh Battery Energy Storage System (BESS) Gigafactory at E-Mobility Valley in the Electronics Manufacturing Cluster, Maheshwaram near the city on Wednesday (April 30, 2025).
The IIT-Madras incubated energy storage engineering and manufacturing company has established the 1,60,000 sq ft facility on a five-acre campus with an investment of ₹100 crore.
Three lines are operational in Phase I. In Phase II, the Gigafactory's capacity will be raised to 10.8 GWh with the addition of 6GWh in the existing facility at an additional investment of ₹150 crore.
1,000 jobs
Across the two phases, in two years from now, more than 1,000 direct and indirect jobs will be generated, founder and CEO Venkat Rajaraman told media after CEO Industry & Investment Cell in Telangana CMO Jayesh Ranjan inaugurated the first phase in the presence of IIIT-Hyderabad Chairman Ashok Jhunjhunwala, iLabs Group founder Srini Raju and others.
High-capacity battery packs for electric vehicles and energy storage systems will be produced at the facility. The advanced BESS systems will cater to large grid-scale stationary storage projects and independent power producers (IPPs). The company has orders for 1 GWh from BESS developers and automotive customers.
As part of the proposed expansion, the company would add three additional automated two GWh cell-to-pack manufacturing lines and container integration facilities to meet the rising demand for stationary and e-mobility storage applications, Cygni Energy said in a release.
'We plan to grow exponentially in energy storage over the next few years in India and internationally,' Mr. Rajaraman said. To queries, he said besides the seed funding from IIT Madras, the company had raised $6.5 million in 2018 and $12.5 million in 2022.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
28 minutes ago
- Time of India
Advent International to acquire stake in Felix Pharmaceuticals
Advent International , a leading global private equity investor , signed a definitive agreement to invest $175 million via primary and secondary for a significant minority stake in Dublin-headquartered Felix Pharmaceuticals , a leading global generic animal pharma player, stated a company release. Felix Pharma is a manufacturer of off-patent medicines for companion animals. Felix develops, manufactures and supplies to distributors and other branded generic players for private labelling, particularly in the US. With a portfolio of 14 approved products from USFDA and many more under review and development, Felix has the widest portfolio of products in the industry. 'Felix is well positioned to lead this generic space with its strong leadership, broad portfolio, and robust R&D and commercial capabilities. Its rapid growth and high customer satisfaction make it a differentiated platform, and we are excited to support Neeraj and the Felix team in scaling it into a global franchise,' said Shweta Jalan, Managing Partner at Advent. Felix was founded in 2015 by Neeraj Agrawal, Sir Jonathan Symonds and Dr Shumeet Banerji, ex-CEO of Booz-Allen. While the company achieved its first US FDA approval in 2020, marking a pivotal step in its expansion, it has quickly scaled to a 14 commercialised product portfolio and has several others in advanced stages of pipeline, it said. It has a USFDA approved oral solid facility dedicated for animal health products and an injectable facility that is expected to be ready by Q3 2025. Neeraj Agrawal, Co-Founder of Felix Pharma, said, 'As we scale in a fast-evolving market, we were looking for a partner who brings not just capital, but also deep operating expertise and the right mindset and networks to help us grow faster and stronger.'
Time of India
29 minutes ago
- Time of India
Sanlayan raises Rs186 crore from investors including Ashish Kacholia, Lashit Sanghvi and Jungle Ventures
Mumbai: Sanlayan Technologies , an aerospace and defence firm, has raised Rs186 crore in its latest round of Series A funding led by investors Ashish Kacholia , Lashit Sanghvi and Jungle Ventures , with participation from existing investors Gemba Capital, Singularity Ventures, and new investor Shastra VC. Previously, Sanlayan raised Rs36 crore in March 2024 in a transaction led by Singapore-headquartered Jungle Ventures. They acquired a majority stake in Dexcel Electronics, an ESDM firm that has contributed to programs including Jaguar, Sukhoi, LCA Tejas and Chandrayaan-3 . 'Sanlayan's ability to execute at both operational and strategic levels has been outstanding. The revenue ramp-up at Dexcel, combined with strategic capital and Sanlayan's operating discipline, reinforces our confidence in their ability to scale sustainably across the defence electronics value chain,' said Rishab Malik, Partner at Jungle Ventures. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 착용했을 때, 더 뿌듯한 팔찌 유니세프 지금 기부하기 Undo Sanlayan is also developing AESA Radar for India's unmanned underwater vehicle (UUV) program, with its in-house R&D capabilities. They have formed partnerships with five Indian startups and foreign OEMs for joint development of cutting-edge solutions. The Bengaluru-based firm, has a three-pronged approach for capability development: acquiring and building upon established Indian defence MSMEs; developing in-house technologies; and forging global alliances. With fresh access to capital, the startup is positioned to double down on this approach and contribute towards programs of national strategic importance, it said. Live Events 'India's defence sector is at a once-in-a-generation inflection point. We will continue to acquire capabilities both organically and inorganically. We are allocating capital for suo-moto development of critical technologies for CUAS and EW systems. In the last six months, we have strengthened Dexcel's design and manufacturing capabilities and are now gearing up to execute large-scale indigenisation and upgrade programs,' said Rohan Gala, co-founder and CEO of Sanlayan. The company plans to increase its engineering headcount fivefold in the next six months. The startup is actively hiring domain experts, R&D scientists, retired armed forces veterans, and senior leadership from both public sector undertakings and private defence giants. "What drew us to Sanlayan was their clear understanding of India's defenceelectronics landscape, and their hybrid strategy to solve it. This is not just a business opportunity; it's a national imperative. We're proud to back a team that's accelerating indigenous capability and contributing meaningfully to India's national security ,' said Ashish Kacholia.
Mint
an hour ago
- Mint
Advent to acquire significant minority stake in animal drug maker Felix Pharmaceuticals for $175 million
Private equity firm Advent International has signed a definitive agreement to invest $175 million (about ₹ 1,500 crore) for a significant minority stake in Felix Pharmaceuticals Pvt. Ltd, an Ireland-headquartered company focused on developing and manufacturing generic medicines for companion animals such as dogs, cats, and horses. This marks another bet by Advent in the growing healthcare space, this time tapping into the under-penetrated animal health generics segment, where branded drugs continue to dominate. Founded in 2015, Felix Pharma is among the fastest-growing companies in the animal health space, with 14 USFDA-approved products and several more in the pipeline. The company primarily supplies to distributors and other branded generics players, especially in the US, through private labelling. 'Felix has an opportunity to shape the companion animal health generics market. The industry is nascent, with less than 10% share held by generic players, providing a long-term growth opportunity,' said Pankaj Patwari, managing director at Advent, in a statement. 'As we scale in a fast-evolving market, we were looking for a partner who brings not just capital, but also deep operating expertise and the right mindset and networks to help us grow faster and stronger,' said Neeraj Agrawal, co-founder of Felix. 'Advent's strong track record in healthcare and pharma, and their close involvement in building strong businesses, gives us great confidence,' he added. Felix was co-founded by Neeraj Agrawal, a McKinsey alum, Sir Jonathan Symonds, chair of GSK, and Dr. Shumeet Banerji, former CEO of Booz Allen Hamilton. The company received its first USFDA approval in 2020, and now operates a dedicated R&D centre and a USFDA-approved manufacturing plant for animal health products. The facility includes dedicated oral solids and liquids capabilities tailored specifically for the veterinary generics market. 'Healthcare has been a long-standing focus for us, and strong parallels we see between success in human Gx [generics] globally and emerging opportunity in animal health Gx,' said Shweta Jalan, managing partner at Advent. 'Felix is well positioned to lead this space with its strong leadership, broad portfolio, and robust R&D and commercial capabilities,' she said. The deal comes amid a sharp rise in global demand for animal drugs, as pet ownership and spending on pet healthcare rise across geographies. Advent has been actively investing in Indian healthcare and financial services. In April 2024, it acquired a 12.1% stake in Apollo Healthco, a unit of Apollo Hospitals, for ₹ 2,475 crore. Last year, it invested $230 million in Svatantra Microfin along with Multiples PE, and exited Bharat Serums and Vaccines, selling it to Mankind Pharma for ₹ 13,630 crore.
